A pharmaceutical investment may seem like a matter far from everyday life until you ask yourself where the laboratories will be built, where the medicines will be produced or in which country the clinical trials that will bring a new therapy to patients will take place. It is from this perspective that Roche’s decision should be read: the Swiss group has paused decisions on new investments in Germany, contesting the policies to contain healthcare costs.
The news does not mean that Roche is leaving the country, that it has stopped ongoing construction or that German patients today risk not finding their medicines. It means that, at least for the moment, the company wants to understand whether German rules will offer sufficiently stable conditions to commit new capital. It is a corporate choice, but also a signal in a comparison that concerns the whole of Europe: how to keep together the sustainability of healthcare systems and the ability to attract research and production?
What Roche really decided
“We have put all decisions on future investments in Germany on hold,” said Daniel Steiners, head of Roche in the country, in an interview with the newspaper Welt. The manager criticized the measures taken to contain German public health costs, claiming that they have reduced the industry’s trust in institutions.
The wording is important: Roche has suspended future decisions, it has not announced the cancellation of investments already approved. Among these is the project in Penzberg, Bavaria, where the company is building a new production center for diagnostics.
Upcoming decisions, such as where to expand production, open a lab or locate a research project, could be postponed until the company has more clarity on the rules.
| The news | What do we know |
|---|---|
| Future decisions | Roche has put them on hold in Germany |
| Projects already started | The production center in Penzberg, worth more than 600 million euros, is not involved |
| Effects on patients | No immediate cuts to treatment or medications have been announced |
| Reason for the comparison | Roche disputes the savings measures and calls for more predictable conditions |
Because Berlin wants to contain healthcare spending
The decision comes after the approval of the German public health insurance reform, the GKV system. Like many European systems, the German one also faces increasing pressure on the accounts: healthcare spending increases, while the government tries to prevent the deficit from translating into higher contributions for citizens and businesses.
Estimates from the German Ministry of Health indicate a potential deficit of around 19 billion euros in 2027, which could rise to 44 billion in 2030 in the absence of interventions. The law approved by the Bundestag on July 10 aims to curb the growth of expenses in various areas of the system. The government presents it as a necessary measure to stabilize contributions and guarantee the financial stability of public healthcare.
It is a concrete need, not an accounting detail. For families, in fact, the cost of healthcare can come through contributions and taxes, but also through expenses incurred directly when public services are unable to respond in adequate time. This is why the discussion cannot be reduced to a simple contrast between businesses and citizens: the system must be able to pay for care today without compromising the resources necessary for those of tomorrow.
Roche, for its part, argues that focusing on short-term savings does not solve the structural problems of health insurance. It is the position of the company, which has a direct interest in defending the economic conditions of the sector. The German government, however, maintains that limiting spending growth is essential to avoid increases in contributions and keep the system sustainable. The point of friction lies in the way in which the cost of the reform is distributed and in the effect that the new rules can have on industrial choices.
What’s at stake: capital, skills and research
Roche’s move also comes after Eli Lilly, in June, announced that it wanted to halve its planned investments in Germany, initially equal to 2.3 billion euros. Even in that case, the comparison with German health policies was at the center of the story. Two decisions are not enough to talk about an exodus from the pharmaceutical industry, but they are enough to rekindle attention on the conditions that companies consider when choosing where to invest.
Germany, however, remains an important hub for Roche. The company inaugurated a diagnostic innovation center worth around 300 million euros in Penzberg in February 2026. Added to this is the new production center worth over 600 million. They are different projects and in different phases, but they show why the suspension of new decisions should be read as a warning about future choices, not as the cancellation of what has already been achieved or started.
Europe is already at the center of global competition
The German case is part of a broader discussion. In September, the heads of nine European pharmaceutical companies, including Roche, called on the European Union and national governments to invest more in the sector, speed up clinical trials and strengthen intellectual property protection.
Europe’s share of global pharmaceutical research and development has fallen from 43% in 1990 to 31%; that in commercial clinical trials has halved in the last decade, to 9%. Businesses point to competition from the United States and China as one reason why Europe should make its ecosystem more attractive. They are data and assessments presented by the industry: they reflect the companies’ point of view, but help to understand why Roche’s decision is also observed beyond German borders.
Pharmaceutical competitiveness, in fact, does not depend on just one factor. The cost of drugs matters, but also how long it takes to start a study, obtain authorizations, negotiate reimbursement and bring a therapy to patients. Research that originates in Europe but is developed or marketed elsewhere can create value in other countries: including qualified employment, know-how and production activities.
For those who take care, the effect of these dynamics is neither immediate nor automatic. Roche’s pause does not prove that a therapy will be delayed or that access to drugs will worsen. The risk, if anything, is measured over time: a territory that loses its attractiveness may be less often chosen for new activities and this may affect the research and production network on which the future availability of innovation depends.
Because the story also concerns Italy
Italy observes this match from a particular position: it is a country with a significant pharmaceutical and production chain, but it must continue to attract capital and high-value-added processes. QuiFinanza reported on the weight of the third-party pharmaceuticals sector: according to the analysis published on the topic, the Italian sector is worth 4.3 billion euros and represents approximately 24% of the European market.
Even for our country, therefore, the question is not just how much is spent on healthcare. It’s understanding how to make the protection of public finances compatible with an environment in which companies and research centers have concrete reasons to invest. Italian healthcare spending is increasing and this does not always translate into more accessible services or a structural strengthening of the National Health Service.
Keeping budgets under control is necessary. Equally necessary is to prevent immediate savings from weakening the capabilities needed to produce innovation, attract skills and guarantee care over time. There is no simple solution, nor can a company’s choice alone dictate healthcare policies, but when a group like Roche puts future decisions on hold, the message also concerns the quality of the rules and the trust that a system can offer.
For patients there is no direct consequence announced today. For governments and industry, however, the challenge is already open: finding a balance in which the sustainability of healthcare is not only measured by the savings obtained in the following year, but also by the ability to continue to innovate and produce in Europe.
